My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Fortress Biotech, Inc. - Common Stock (NQ:FBIO)

3.360 -0.120 (-3.45%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Fortress Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 14, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 17, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

December 21, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 14, 2022

Via Benzinga

Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions

October 06, 2022

By Rachael Green, Benzinga

Via News Direct

Fortress Biotech: Q2 Earnings Insights ↗

August 11, 2022

Fortress Biotech (NASDAQ:FBIO) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Fortress Biotech Q4 Earnings ↗

March 28, 2022

Fortress Biotech (NASDAQ:FBIO) reported its Q4 earnings results on Monday, March 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

December 23, 2022

OnFriday, 143 stocks hit new 52-week lows.

Via Benzinga

Fortress Bio's Portfolio Of Marketed Drugs Could Soon See Three Additions ↗

October 05, 2022

Fortress Biotech Inc. (NASDAQ: FBIO) is a biopharmaceutical company focused on developing a range of high-potential treatments on its own and through its growing portfolio of subsidiaries and partner...

Via Benzinga

Fortress Biotech Earnings Perspective: Return On Capital Employed ↗

September 08, 2022

Benzinga Pro data, Fortress Biotech (NASDAQ:FBIO) reported Q2 sales of $18.89 million. Earnings fell to a loss of $53.93 million, resulting in a 9.0% decrease from last quarter.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 12, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022 ↗

August 04, 2022

Upgrades

Via Benzinga

B. Riley Securities Maintains Buy Rating for Fortress Biotech: Here's What You Need To Know ↗

July 14, 2022

B. Riley Securities has decided to maintain its Buy rating of Fortress Biotech (NASDAQ:FBIO) and lower its price target from $8.00 to $6.00. Shares of Fortress Biotech are trading down 1.01% over the...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 06, 2022

Gainers

Via Benzinga

Looking Into Fortress Biotech's Return On Capital Employed ↗

March 29, 2022

Benzinga Pro data, Fortress Biotech (NASDAQ:FBIO) reported Q4 sales of $18.28 million. Earnings fell to a loss of $68.51 million, resulting in a 49.38% decrease from last quarter.

Via Benzinga

Benzinga Announces This Week's All Access Guests ↗

February 10, 2022

Benzinga is thrilled to announce the guest lineup for our next All Access show, sponsored by TiiCKER, set to air Friday, February 11 at 9:15 am ET. The Lineup 9:15 am...

Via Benzinga

FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder ↗

January 25, 2022

The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Drug (IND)...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 02, 2022

Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

December 15, 2021

Gainers Calliditas Therapeutics (NASDAQ:

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 15, 2021

Gainers Kezar Life Sciences (NASDAQ:KZR) s...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 14, 2021

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 34.63% to $12.71 during Thursday's pre-market session. The company's market cap stands at $683.4...

Via Benzinga

18 Stocks Moving in Thursday's Pre-Market Session ↗

October 14, 2021

Gainers TSR, Inc. (NASDAQ: TSRI) rose 40.2% to $12.89 in pre-market trading after the company reported record revenue for its first quarter. Cemtrex, Inc. (NASDAQ: CETX) rose 34....

Via Benzinga

The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts ↗

October 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc...

Via Benzinga

Fortress-Backed Cyprium's Formulated Copper Histidinate Shows Efficacy In Rare Pediatric Disease ↗

October 08, 2021

Fortress Biotech Inc's (NASDAQ: FBIO) partner company, Cyprium Therapeutics Inc announced results from an efficacy and safety analysis of data ...

Via Benzinga

33 Stocks Moving In Wednesday's Mid-Day Session ↗

September 29, 2021

Gainers Paltalk, Inc. (NASDAQ: PALT) shares climbed 37% to $7.18. NuCana plc (NASDAQ: NCNA) jumped 31.4% to $3.1150. The FDA granted Fast Track designation to NuCana’s...

Via Benzinga

52 Biggest Movers From Yesterday ↗

September 30, 2021

Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share...

Via Benzinga

AstraZeneca Buys Fortress-Biotech Founded Caelum For $500M ↗

September 29, 2021

AstraZeneca Plc (NASDAQ: AZN) will take complete control of Caelum Biosciences in a deal worth up to $500 million, sharpening its focus on rare-disease...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 29, 2021

Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6...

Via Benzinga

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 18, 2021

Gainers Protagenic Therapeutics (NASDAQ:PTIX...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.